GlassScriptPhysician profile
Sajid Shaik
NPI 1588397053
$1,405.60
in general payments reported to CMS, 2019-2025
15 companies · $399 in 2025
The $399 reported for 2025 was more than what 75% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $162 · 2023: $462 · 2024: $382 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,243.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $374.86 | 2022-2025 | Qulipta, Botox |
| E.R. Squibb & Sons, L.L.C. | $243.30 | 2023-2025 | Opdivo, Camzyos |
| Astrazeneca Pharmaceuticals LP | $200.80 | 2022-2025 | Farxiga, Imfinzi, Airsupra |
| Amgen INC. | $114.62 | 2024-2025 | Evenity |
| Alexion Pharmaceuticals, INC. | $105.99 | 2022-2024 | Ultomiris |
| Alnylam Pharmaceuticals INC. | $89.99 | 2025 | Onpattro |
| Glaxosmithkline, LLC. | $58.55 | 2023-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $43.96 | 2024 | Entyvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.28 | 2022-2025 | |
| Novo Nordisk INC | $33.94 | 2025 | Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $29.89 | 2024 | |
| Grifols USA, LLC | $20.11 | 2024 | Gamunex-C |
| Karyopharm Therapeutics INC. | $18.44 | 2024 | Xpovio |
| Alcresta Therapeutics, INC. | $16.36 | 2023 | Relizorb |
| Janssen Pharmaceuticals, INC | $15.51 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajid Shaik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.